Pharmacological activation of PPARα, inhibition of excessive mitochondrial fission, or alleviation of LD degradation defects effectively blocked this pathological cascade and mitigated CIH-induced PD susceptibility, highlighting potential therapeutic targets for reducing PD risk in patients with OSA. Here, PPARA is linked to obstructive sleep apnea syndrome.